The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.

@article{Mcdermott2015TheHA,
  title={The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.},
  author={D F Mcdermott and Su-Chun Cheng and Sabina Signoretti and Kim A Margolin and Joseph I Clark and Jeffrey A. Sosman and Janice P Dutcher and Theodore F. Logan and Brendan D. Curti and Marc S. Ernstoff and Leonard Joseph Appleman and Michael K. K. Wong and Nikhil I. Khushalani and Leslie Oleksowicz and Ulka Vaishampayan and James Walter Mier and David J. Panka and Rupal S. Bhatt and Alexandra S Bailey and Bradley C. Leibovich and Eugene D. Kwon and Fairooz F. Kabbinavar and Arie S. Belldegrun and Robert Alan Figlin and Allan J. Pantuck and Meredith M. Regan and Michael B. Atkins},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2015},
  volume={21 3},
  pages={561-8}
}
PURPOSE High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2. EXPERIMENTAL DESIGN Standard HD IL2 was administered to prospectively… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

IL-2 and Beyond in Cancer Immunotherapy.

Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research • 2018

Similar Papers

Loading similar papers…